
Join to View Full Profile
1250 E Marshall StInternal MedicineRichmond, VA 23298
Phone+1 804-828-5211
Fax+1 804-828-9692
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 4 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Steven Grant, MD is an oncologist in Richmond, Virginia. He is currently licensed to practice medicine in Virginia. He is a Professor at Virginia Commonwealth University School.
Education & Training
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1973 - 1978
Icahn School of Medicine at Mount SinaiClass of 1973
Certifications & Licensure
VA State Medical License 1987 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification PowerChart, FirstNet, HealthSentry and P2 Sentinel, Cerner Corporation, 2014-2015
- CMS Meaningful Use Stage 1 Certification Cerner Millennium Powerchart, Cerner Millennium FirstNet, Cerner Millennium ProFile, Health Sentry, Healthe Exchange, Cerner Healthe Record, IQHealth and P2 Sentinel (Powered by Sensage), Cerner Corporation, 2014-2015
Publications & Presentations
PubMed
- 1 citationsAcid ceramidase controls proteasome inhibitor resistance and is a novel therapeutic target for the treatment of relapsed/refractory multiple myeloma.Ryan T Bishop, Tao Li, Praneeth Sudalagunta, Mostafa Nasr, Karl J Nyman
Haematologica. 2025-06-01 - 8 citationsSrc inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia.Xiaoyan Hu, Lin Li, Jewel Nkwocha, Maciej Kmieciak, Shengzhe Shang
Signal Transduction and Targeted Therapy. 2025-02-10 - 14 citationsA phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.Keri R Maher, Danielle Shafer, Dale Schaar, Dipankar Bandyopadhyay, Xiaoyan Deng
Cancer Chemotherapy and Pharmacology. 2025-01-17









